
    
      Patients who have completed 3 years follow-up of the past Beijing Science and Technology
      Commission Research will receive another 7-years anti-viral therapy. Patients will be
      assessed at baseline and every six months for blood cell count, liver function test, HBVDNA,
      AFP, prothrombin time, liver ultrasonography, and Fibroscan. CT or MRI and endoscopy will be
      performed at baseline and 7 years. At the end of the study, the cumulative rate of clinical
      hepatic hard endpoint will be calculated.
    
  